Merck OnCall® is an innovative way for you to connect with Merck, providing immediate access to a representative when you need information about Merck products or services. No special technology is required, and it’s easy and convenient to use: all you need is a telephone and an Internet connection to get started. Start your session to receive instant access to a representative for ZETIA at your convenience.
During your live electronic product presentation, you can:
- Request samples and vouchers for Merck products
- Obtain the latest product information for Merck products
- Have access to relevant clinical articles
- Request educational materials for your patients
- Receive assistance with registration for Merck eMedical Forums
- Get answers to questions about diseases relevant to
Merck products
 |
The effect of ZETIA on cardiovascular morbidity and mortality has not been determined. |
|
ZETIA, administered alone or in combination with an HMG-CoA reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elevated TOTAL-C, LDL-C, and Apo B in patients with primary (heterozygous familial and nonfamilial) hyperlipidemia when diet alone is not enough. |
| SELECTED CAUTIONARY INFORMATION | |
|
| ZETIA is not recommended in patients with moderate to severe hepatic impairment. |
|
The coadministration of ZETIA with fibrates other than fenofibrate is not recommended until use in patients is adequately studied. |
|
Exercise caution when using ZETIA and cyclosporine concomitantly because exposure to both drugs is increased. Cyclosporine concentrations should be monitored in these patients. |
|
ZETIA should be used in pregnant or nursing women only if the benefit outweighs the risk. |
|
In clinical trials, regardless of causality assessment, the most frequent side effects for ZETIA coadministered with a statin vs statin alone included nasopharyngitis (3.7% vs 3.3%), myalgia (3.2% vs 2.7%), upper respiratory tract infection (2.9% vs 2.8%), arthralgia (2.6% vs 2.4%), and diarrhea (2.5% vs 2.2%); for ZETIA administered alone vs placebo: upper respiratory tract infection (4.3% vs 2.5%), diarrhea (4.1% vs 3.7%), arthralgia (3.0% vs 2.2%), sinusitis (2.8% vs 2.2%), pain in extremity (2.7% vs 2.5%), and fatigue (2.4% vs 1.5%). |
Before prescribing ZETIA, please read the Prescribing Information.
This site is intended only for health care professionals of the United States, its territories, and Puerto Rico.
For non-US health care professionals, click here.
ZETIA and VYTORIN are registered trademarks of MSP Singapore Company, LLC.
MerckMedicus™, MerckSource®, and MerckServices® are trademarks of Merck & Co., Inc.
Merck OnCall® is a registered trademark of Merck & Co., Inc.
Copyright © 2010 Merck/Schering-Plough Pharmaceuticals, a subsidiary of Merck & Co., Inc. All rights reserved.
21050228(1)-06/10-ZET